

Multiple myeloma

(including plasma cell neoplasms)

Patients diagnosed 1993-2019

(ICD10: C90)

Further information

Further data is available at: www.qub.ac.uk/research-centres/nicr

Phone: +44 (0)28 9097 6028

e-mail: nicr@qub.ac.uk

Acknowledgements

The Northern Ireland Cancer Registry (NICR) is funded by the Public Health Agency and is based in Queen's University, Belfast. NICR uses data provided by patients and collected by the health service as part of their care and support.

The incidence, prevalence and survival statistics in this publication are designated as official statistics signifying that they comply with the Code of Practice for Official Statistics.



Incidence

During 2015-2019:


- There were 99 male and 72 female cases of multiple myeloma diagnosed each year.
- Multiple myeloma made up 2.0% of all male, and 1.5% of all female cancers (ex NMSC).
- The risk of developing multiple myeloma before the age of 75 was 1 in 144.4 for men and 1 in 257.6 for women, while before the age of 85 the risk was 1 in 75.1 for men and 1 in 124.4 for women.

Incidence by age at diagnosis - Multiple myeloma, Cases in 2015-2019

During 2015-2019:

- The median age at diagnosis was 70 for men and 74 for women.
- Cancer risk varied by age, with 35.4% of men and 45.8% of women aged 75 years or more at diagnosis.
- 9.9% of cases were diagnosed among those aged under 55.


Age at diagnosis	Average cases per year		
	Male	Female	Both sexes
0 - 54	11	6	17
54 - 64	17	12	30
65 - 74	36	19	55
75 +	35	33	69
All ages	99	72	171



Incidence by year of diagnosis - Multiple myeloma, Cases in 1995-2019

- Among males the number of cases of multiple myeloma increased by 39.4% from an annual average of 71 cases in 2010-2014 to 99 cases in 2015-2019.
- Among females the number of cases of multiple myeloma increased by 28.6% from an annual average of 56 cases in 2010-2014 to 72 cases in 2015-2019.

Year of diagnosis	Male	Female	Both sexes
2010	54	53	107
2011	79	53	132
2012	63	41	104
2013	75	57	132
2014	82	75	157
2015	87	71	158
2016	98	78	176
2017	107	69	176
2018	98	61	159
2019	105	81	186




Note: Annual averages have been rounded to the nearest integer. Sums of numbers in table rows or columns may thus differ slightly from the given total.

NMSC: Non-melanoma skin cancer

Trends in age-standardised incidence rates - Multiple myeloma, Cases in 1995-2019

- Among males age-standardised incidence rates of multiple myeloma increased by 21.6% from 11.1 per 100,000 person years in 2010-2014 to 13.5 cases per 100,000 persons years in 2015-2019. This difference was statistically significant.
- Among females age-standardised incidence rates of multiple myeloma increased by 18.8% from 6.9 per 100,000 person years in 2010-2014 to 8.2 cases per 100,000 persons years in 2015-2019. This difference was not statistically significant.



Age-standardised incidence rates illustrate the change in the number of cases within a population of a fixed size and age structure (2013 European Standard).

They thus represent changes other than those caused by population growth and/or ageing.

Trends can also be influenced by changes in how cancer is classified and coded. (e.g. the move from ICD-0-2 to ICD-0-3 in 2019).

Incidence by deprivation quintile - Multiple myeloma, Cases in 2015-2019

The annual number of cases during 2015-2019 varied in each deprivation quintile due to variations in population size and age.

After accounting for these factors, incidence rates:


- in the most socio-economically deprived areas did not vary significantly from the NI average.
- in the least socio-economically deprived areas did not vary significantly from the NI average.

Deprivation quintile	Average cases per year		
	Male	Female	Both sexes
Least deprived (Quintile 1)	20	18	38
Quintile 2	22	17	39
Quintile 3	22	13	36
Quintile 4	20	13	33
Most deprived (Quintile 5)	14	11	26
Northern Ireland	99	72	171

Standardised incidence ratios compare incidence rates in each deprivation quintile with the Northern Ireland incidence rate.

A value above 100 means that incidence rates in that deprivation quintile are greater than the Northern Ireland average.

This measure takes account of population size and age structure. Differences are thus not a result of these factors.




Incidence by Health and Social Care Trust (HSCT) - Multiple myeloma, Cases in 2015-2019

The annual number of cases during 2015-2019 varied in each HSCT due to variations in population size and age.

After accounting for these factors, incidence rates:

- in Belfast HSCT did not vary significantly from the NI average.
- in Northern HSCT did not vary significantly from the NI average.
- in South-Eastern HSCT were significantly lower than the NI average.
- in Southern HSCT were significantly higher than the NI average.
- in Western HSCT did not vary significantly from the NI average.

Health and Social Care Trust	Average cases per year		
	Male	Female	Both sexes
Belfast HSCT	17	14	32
Northern HSCT	27	18	45
South-Eastern HSCT	18	11	29
Southern HSCT	21	16	37
Western HSCT	16	12	28
Northern Ireland	99	72	171



Standardised incidence ratios compare incidence rates in each HSC Trust with the Northern Ireland incidence rate. A value above 100 means that incidence rates in that HSC Trust are greater than the NI average.

This measure takes account of population size and age structure. Differences are thus not a result of these factors.


Data for Local Government Districts and Parliamentary Constituencies are available at www.qub.ac.uk/research-centres/nicr

Incidence by method of most recent admission to hospital - Multiple myeloma, Cases in 2015-2019

During 2015-2019:

- 24.4% of cases had an emergency admission to hospital recorded up to 30 days prior to their cancer diagnosis.
- 23.0% of male cases had an emergency admission up to 30 days prior to diagnosis, compared to 26.4% of female cases.
- In 36.6% of diagnosed cases there was no record of a hospital inpatient admission up to 30 days prior to diagnosis.

Method of admission	Average cases per year		
	Male	Female	Both sexes
Emergency admission	23	19	42
Elective admission	39	28	67
No emergency/elective admission recorded	37	25	63
Total	99	72	171



Admission method refers to the most recent hospital inpatient admission that a patient had prior to cancer diagnosis, regardless of reason for the admission.

Admissions are considered up to a maximum of 30 days prior to diagnosis. Admissions up to two days post diagnosis are also considered to allow for a reasonable margin or error in data recording.

The majority of patients with no inpatient admission recorded prior to diagnosis are likely to have been diagnosed via an outpatient route.


Survival

- 76.7% of patients were alive one year and 39.1% were alive five years from a multiple myeloma diagnosis in 2010-2014. (observed survival)
- Age-standardised net survival (ASNS), which removes the effect of deaths from causes unrelated to cancer, was 84.1% one year and 51.8% five years from a multiple myeloma diagnosis in 2010-2014.
- Five-year survival (ASNS) for multiple myeloma patients diagnosed in 2010-2014 was 50.4% among men and 53.8% among women.

Gender	Observed survival		Age-standardised net survival	
	One-year	Five-years	One-year	Five-years
Male	77.9%	40.0%	83.3%	50.4%
Female	75.1%	37.9%	85.3%	53.8%
Both sexes	76.7%	39.1%	84.1%	51.8%


Observed survival is the proportion of patients still alive one/five years after diagnosis. However, in this measure patients may have died from causes unrelated to their cancer.

Age-standardised net survival is the proportion of patients who would survive if the patient could not die from causes unrelated to their cancer. This measure is more typically used in studies of cancer survival.




Trends in survival - Multiple myeloma, Patients diagnosed in 1995-2014

- Among men five-year survival (ASNS) from multiple myeloma increased from 49.4% in 2005-2009 to 50.4% in 2010-2014. This difference was not statistically significant.
- Among women five-year survival (ASNS) from multiple myeloma increased from 53.3% in 2005-2009 to 53.8% in 2010-2014. This difference was not statistically significant.




Survival by method of most recent admission to hospital - Multiple myeloma, Patients diagnosed in 2010-2014

- Five-year survival (ASNS) among multiple myeloma patients who had an emergency admission to hospital up to 30 days prior to their cancer diagnosis was 38.6% compared to 60.5% among those with elective admissions and 52.2% among those who had no hospital admissions recorded up to 30 days prior to diagnosis.



Survival by age at diagnosis - Multiple myeloma, Patients diagnosed in 2010-2014

- Survival from multiple myeloma among patients diagnosed in 2010-2014 was strongly related to age with better five-year survival among younger age groups. In particular:
 - Five-year net survival was 64.8% among patients aged 15 to 54 at diagnosis, compared to 29.5% among those aged 75 and over.
 - Five-year net survival among patients aged 75 and over was 25.0% for men and 33.5% for women.



Prevalence

- At the end of 2019, there were 900 people (Males: 513; Females: 387) living with multiple myeloma who had been diagnosed with the disease during 1995-2019.
 - Of these, 57.0% were male, 40.3% were aged 75 and over, and 18.3% had been diagnosed in the previous year.

25-year prevalence refers to the number of cancer survivors who were alive at the end of 2019, and had been diagnosed with their cancer in the previous 25 years (i.e. 1995-2019).

Time since diagnosis	25-year prevalence								
	Aged 0-74			Aged 75+			All ages		
	Male	Female	Both sexes	Male	Female	Both sexes	Male	Female	Both sexes
0-1 year	61	36	97	34	34	68	95	70	165
1-5 years	157	104	261	87	76	163	244	180	424
5-10 years	62	31	93	34	39	73	96	70	166
10-25 years	47	39	86	31	28	59	78	67	145
0-25 years	327	210	537	186	177	363	513	387	900

Trends in 10-year prevalence - Multiple myeloma, Patients alive at end of each year from 2010-2019

- Among males the number of survivors from multiple myeloma who had been diagnosed within the previous ten years increased by 27.6% from 341 survivors in 2014 to 435 survivors in 2019.
- Among females the number of survivors from multiple myeloma who had been diagnosed within the previous ten years increased by 32.8% from 241 survivors in 2014 to 320 survivors in 2019.

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Male	282	296	310	336	341	345	373	387	410	435
Female	220	221	222	233	241	254	273	283	299	320
Both sexes	502	517	532	569	582	599	646	670	709	755

Mortality

- During 2015-2019 there were 50 male and 37 female deaths from multiple myeloma each year.
- Multiple myeloma made up 2.1% of all male, and 1.8% of all female cancer deaths (ex NMSC).

Deaths by age at death - Multiple myeloma, Deaths in 2015-2019

- The median age at death during 2015-2019 was 76 for men and 79 for women.
- Risk of death from multiple myeloma was strongly related to patient age, with 54.0% of men and 67.6% of women aged 75 years or more at time of death.
- 4.6% of multiple myeloma deaths occurred among those aged under 55.

Age at death	Average deaths per year		
	Male	Female	Both sexes
0 - 54	3	1	4
55 - 64	5	3	8
65 - 74	15	7	22
75 +	27	25	52
All ages	50	37	87


Deaths by year of death - Multiple myeloma, Deaths in 2010-2019

- Among males the number of deaths from multiple myeloma increased by 42.9% from an annual average of 35 deaths in 2010-2014 to 50 deaths in 2015-2019.
- Among females the number of deaths from multiple myeloma increased by 2.8% from an annual average of 36 deaths in 2010-2014 to 37 deaths in 2015-2019.

	2010	2011	2012	2013	2014	2015	2016	2017	2018	2019
Male	32	39	30	33	42	52	51	45	56	44
Female	31	32	29	41	45	40	38	33	31	43
Both sexes	63	71	59	74	87	92	89	78	87	87

Trends in age-standardised mortality rates - Multiple myeloma, Deaths in 1995-2019

- Among males age-standardised mortality rates from multiple myeloma increased by 23.7% between 2010-2014 and 2015-2019 from 5.9 to 7.3 deaths per 100,000 persons years. This difference was not statistically significant.
- Among females age-standardised mortality rates from multiple myeloma decreased by 4.5% between 2010-2014 and 2015-2019 from 4.4 to 4.2 deaths per 100,000 persons years. This difference was not statistically significant.



Mortality data are provided by the Northern Ireland General Registrar Office via the Department of Health.

Counts of the number of deaths are based upon the year that death occurred, and upon the primary cause of death only.

Age-standardised mortality rates remove changes over time caused by population growth and/or ageing.

Background notes

Cancer classification: Classification of tumour sites is carried out using ICD10 codes. For a listing and explanation of ICD10 codes see: World Health Organisation at <http://apps.who.int/classifications/icd10/browse/2010/en#/II>

Population data for Northern Ireland, and smaller geographic areas, are extracted from the NI mid-year population estimates available from the NI Statistics and Research Agency (available at www.nisra.gov.uk).

Geographic areas are assigned based on a patient's postcode of usual residence at diagnosis using the Jan 2021 Central Postcode Directory (CPD) produced by the NI Statistics and Research Agency (available at www.nisra.gov.uk).

Deprivation quintiles: Super output areas (SOA) are assigned to each patient based on their postcode of usual residence at diagnosis. Using the SOA each patient is assigned a socio-economic deprivation quintile based on the 2017 Multiple Deprivation Measure. The 2017 Multiple Deprivation Measure is available from the NI Statistics and Research Agency (available at www.nisra.gov.uk).

A **crude incidence/mortality rate** is the number of cases/deaths per 100,000 person years in the population. Person years are the sum of the population over the number of years included.

An **age-standardised incidence/mortality rate** per 100,000 person years is an estimate of the incidence/mortality rate if that population had a standard age structure. Throughout this report the 2013 European Standard Population has been used. Standardising to a common Standard Population allows comparisons of incidence/mortality rates to be made between different time periods and geographic areas while removing the effects of population change and ageing.

A **Standardised Incidence/Mortality Ratio (SIR/SMR)** is the ratio of the number of cases/deaths observed in a population to the expected number of cases/deaths, based upon the age-specific rates in a reference population. This statistic is often used to compare incidence/mortality rates for geographic areas (e.g. Trusts) to the national incidence/mortality rates (i.e. Northern Ireland). An SIR/SMR of 100 indicates there is no difference between the geographic area and the national average.

Confidence intervals are a measure of the precision of a statistic (e.g. colorectal cancer incidence rate). Typically, when numbers are low, precision is poorer and confidence intervals will be wider. As a general rule, when comparing statistics (e.g. cervical cancer incidence rate in year 2012 vs year 2013), if the confidence interval around one statistic overlaps with the interval around another, it is unlikely that there is any real difference between the two. If there is no overlap, the difference is considered to be **statistically significant**.

Lifetime risk is estimated as the cumulative risk of getting cancer up to age 75/85, calculated directly from the age-specific incidence rates. The odds of developing the disease before age 75/85 is the inverse of the cumulative risk.

Prevalence is the number of cancer patients who are alive in the population on a specific date (31st December 2019 in this report). Since data from the NI Cancer Registry are only available since 1993, prevalence only refers to a fixed term (10 and 25 years in this report). There may be members of the population living with a diagnosis of cancer for more than 25 years.

Observed survival refers to the proportion of patients who survive a specified amount of time from their date of diagnosis. Observed survival considers death from any cause and is not adjusted for the age of the patient. Cause of death may be unrelated to the cancer the patient has been diagnosed with.

Net Survival is an estimate of survival where the effect on survival of background population mortality rates has been removed. It represents the [theoretical] survival of cancer patients if they could only die from cancer-related causes. Age-standardised net survival estimates are the estimates that would occur if that population of cancer patients had a standard population age structure. The age groups and weights used here are those used by international studies such as EUROCARE, an international study group that compares cancer survival among European countries. However, due to the small number of patients in NI, the first two age categories in the standard population are combined.

Mortality: Information relating to cancer mortality is sourced from the General Registrar Office (GRONI) via the Department of Health (NI). Results are based upon the date on which death occurs, and may thus differ slightly than those produced by the Northern Ireland Statistics and Research Agency (NISRA), which produces deaths data based upon the date on which the death is registered with GRONI.